Login / Signup

Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells.

Yi-Chiu KuoCheng-Fu KuoKurt JenkinsAlfur Fu-Hsin HungWen-Chung ChangMiso ParkBrenda AguilarRenate StarrJonathan HibbardChristine BrownJohn C Williams
Published in: Journal for immunotherapy of cancer (2022)
Collectively, these findings support the feasibility of this universal Fabrack-CAR T cell approach and provide the rationale for future clinical use in cancer immunotherapy.
Keyphrases
  • current status
  • clinical trial